CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2016—SeraCare Life Sciences launched an expanded product line to support NGS-based somatic tumor profiling assay development, validation, and QC performance monitoring. The eight new Seraseq Solid Tumor Mutation Mix-II products contain 40 somatic variants with increases in the number of insertion-deletion mutations from four to 13 to challenge both the sequencing and variant calling algorithms. There is also the addition of two DNA-level structural variants of actionable gene fusions.
The STMM-II is available in two concentrations and is provided at four percent, seven percent, and 10 percent allelic frequencies, making it an ideal format, the company says, for labs looking to test a nominal assay limit of detection set at five percent. SeraCare provides a single-tube blended reference material format containing 40 variants in a tri-level configuration with mutations at one of 10 percent, seven percent, or four percent allelic frequencies.
The company also announced a co-development partnership with Toma Biosciences. Under the terms of the agreement, SeraCare will provide Toma access to its Seraseq Solid Tumor Mutation Mix reference material technology to support the development and validation of the Toma OS-Seq comprehensive solid tumor gene analysis kit as well as Toma’s upcoming PlasmaSeq liquid biopsy test.
Toma’s OS-Seq proprietary technology permits researchers to evaluate in toto each gene in its panel for all mutation types, including copy number alterations, with a single-day library preparation method.
SeraCare Life Sciences, 508-244-6400
Toma BioSciences, 650-691-8662